Ketamine Therapy in New Mexico

New Mexico follows federal regulations governing the administration of ketamine, which remains a Schedule III controlled substance under the Controlled Substances Act. Clinicians who administer or prescribe ketamine must hold a valid DEA registration and an active state medical license issued by the New Mexico Medical Board. Ketamine infusion therapy is currently administered as an off-label treatment, meaning the FDA has approved ketamine as an anesthetic but not specifically for conditions such as depression, anxiety, PTSD, or chronic pain. This off-label use is legal and widely practiced, but it places additional responsibility on providers to ensure informed consent and evidence-based clinical protocols.

In New Mexico, ketamine clinics typically operate under the supervision of licensed physicians, including anesthesiologists, psychiatrists, and other qualified medical doctors. The New Mexico Medical Board oversees physician conduct and licensing, while the New Mexico Board of Pharmacy regulates the dispensing and handling of controlled substances within the state. Providers must maintain strict documentation practices, including patient evaluations, dosing records, and adverse event reporting, in compliance with both state and federal requirements. Facilities that compound or prepare ketamine solutions must additionally comply with USP standards and any applicable state pharmacy compounding regulations.

Patients seeking ketamine therapy in New Mexico should be aware of the following general regulatory considerations:

• Treatment must be administered or directly supervised by a licensed medical professional with appropriate DEA registration.
• Facilities should conduct thorough pre-treatment medical and psychological evaluations to establish patient suitability.
• Informed consent documentation is required, clearly outlining the off-label nature of the treatment, potential risks, and expected outcomes.
• Esketamine (Spravato), the FDA-approved nasal spray form, must be administered within a certified healthcare setting under a Risk Evaluation and Mitigation Strategy (REMS) program.

The regulatory landscape for ketamine therapy continues to evolve at both the state and federal levels. New Mexico has not enacted specific standalone legislation exclusively targeting ketamine infusion clinics, meaning providers largely operate within existing medical practice and controlled substance frameworks. Patients are encouraged to verify that any clinic they consider is staffed by credentialed professionals, maintains transparent billing and consent practices, and follows current clinical guidelines established by organizations such as the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3).